Русский
Tocilizumab, baricitinib, olokizumab and dexamethasone: comparative characteristics and prognosis of efficacy in COVID-19
DOI: https://dx.doi.org/10.18565/therapy.2022.7.110-116
Sukhomlinova I.M., Bakulin I.G., Kabanov M.Yu.
1) I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, Saint Petersburg; 2) Hospital for War Veterans, Saint Petersburg
The aim of the study: to compare the effectiveness of AIT with dexamethasone, olokizumab, tocilizumab, baricitinib in COVID-19.
Material and methods. A retrospective analysis of 229 cases of severe and moderate course of COVID-19 at Hospital of War Veterans (Saint Petrsburg) was performed, in which AIT was performed with dexamethasone, olokizumab, baricitinib, and tocilizumab. Calculations with a certainty of 95% or more were taken as statistically significant (p <0,05). The Bonferroni correction was used as a method for controlling the group error probability (of the first kind).
Results and conclusion. During the study, differences in the outcome of the disease during AIT were established in the groups, a comparative analysis of patient subgroups was performed depending on the drug used. It was found that patients with an unfavorable outcome of COVID-19 had a later appointment of AIT, they needed more O2 support by the time it started. The volume of lung tissue damage according to the results of CT examination should be compared with the results of laboratory data, among which the most significant are CRP and D-dimer. The use of tocilizumab had the most significant effect on the decrease in mortality in the group of patients studied, and the use of dexamethasone was slightly less significant. At the same time, the significance of the effect of baricitinib and olokizumab on the outcome of AIT was comparable.
Literature
1. Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. с соавт. Международный регистр «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-COV-2» (AКТИВ SARS-CoV-2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции. Российский кардиологический журнал. 2021; 26(4): 116–131. [Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G. et al. International register «Dynamics analysis of comorbidities in SARS-CoV-2 survivors» (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(4): 116–131 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2021-4470. EDN: IEXRNA.
2. Shimabukuro-Vornhagen A., Godel P., Subklewe M. et al. Cytokine release syndrome. J Immunother Cancer. 2018; 6(1): 56.https://dx.doi.org/10.1186/s40425-018-0343-9.
3. Zhang C., Wu Z., Li J.-W. et al. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55(5): 105954. https://dx.doi.org/10.1016/j.ijantimicag.2020.105954
4. Сухомлинова И.М., Бакулин И.Г., Кабанов М.Ю. Противовоспалительная терапия при новой коронавирусной инфекции: эффективность и предикторы ответа. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2021; 14(1): 59–68. [Sukhomlinova I.M., Bakulin I.G., Kabanov M.Yu. Anti-inflammatory therapy for COVID-19: effectiveness and predictors of response. Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta im. I.I. Mechnikova = Herald of the North-Western State Medical University. 2021; 14(1): 59–68 (In Russ.)]. https://dx.doi.org/10.17816/mechnikov96603. EDN: AYUIBS.
5. Liu Y., Wang Z., Ren J. et al. A COVID-19 risk assessment decision support system for general practitioners: Design and development study. J Med Internet Res. 2020; 22(6): e19786. https://dx.doi.org/10.2196/19786.
6. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229): 1054–62. https://dx.doi.org/10.1016/S0140-6736(20)30566-3.
7. Свидетельство о государственной регистрации программы для ЭВМ № 2022611745 Российская Федерация. Оценка прогноза эффективности противовоспалительной терапии при COVID-19: № 2022610740: заявл. 25.01.2022: опубл. 01.02.2022. И.М. Сухомлинова, И.Г. Бакулин, М.Ю. Кабанов, Е.В. Тетерин; заявитель ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России. [Certificate of state registration of the computer program No. 2022611745 Russian Federation. Evaluation of the prognosis of the effectiveness of anti-inflammatory therapy in COVID-19: No. 2022610740: Appl. 01/25/2022: publ. 02/01/2022. Sukhomlinova I.M., Bakulin I.G., Kabanov M.Yu.; applicant I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia (In Russ.)].
8. Свидетельство о государственной регистрации программы для ЭВМ № 2021668598 Российская Федерация. Индекс прогноза эффективности противовоспалительной терапии при COVID-19: № 2021667856: заявл. 12.11.2021: опубл. 18.11.2021. И.М. Сухомлинова, И.Г. Бакулин, М.Ю. Кабанов, А.А. Ивашов; заявитель ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России. [Certificate of state registration of the computer program No. 2021668598 Russian Federation. Anti-inflammatory therapy efficacy prediction index for COVID-19: No. 2021667856: Appl. 11/12/2021: publ. 11/18/2021. Sukhomlinova I.M., Bakulin I.G., Kabanov M.Yu., Ivashov A.A.; applicant I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia (In Russ.)].
9. Эволюция пандемии COVID-19: монография. Под ред. Н.А. Белякова, С.Ф. Багненко. СПб.: Балтийский медицинский образовательный центр. 2021; 410 с. [Evolution of the COVID-19 pandemic: monograph. Ed. by Belyakov N.A., Bagnenko S.F. Saint Petersburg: Baltic Medical Education Center. 2021; 410 pp. (In Russ.)]. ISBN: 978-5-6041808-8-4.
10. Драпкина О.М., Маев И.В., Бакулин И.Г. с соавт. Временные методические рекомендации: «Болезни органов пищеварения в условиях пандемии новой коронавирусной инфекции (COVID-19)». Версия 2. Профилактическая медицина. 2021; 25(5–2): 4–41. [Drapkina O.M., Mayev I.V., Bakulin I.G. et al. Provisional guidelines: «Diseases of the digestive organs in conditions of a pandemic new coronavirus infection (COVID-19)». Version 2. Profilakticheskaya meditsina = Preventive Medicine. 2021; 25(5–2): 4–41 (In Russ.)]. https://dx.doi.org/10.17116/profmed202023032120. EDN: MGLBCN.
11. Сайганов С.А., Мазуров В.И., Бакулин И.Г. с соавт. Клиническое течение, эффективность терапии и исходы новой коронавирусной инфекции: предварительный анализ. Вестник Северо-Западного государственного медицинского университетаим. И.И. Мечникова. 2020; 12(2): 27–38. [Sayganov S.A., Mazurov V.I., Bakulin I.G. et al. Current, effectiveness of therapy and outcomes of new coronavirus infection: preliminary analysis. Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta im. I.I. Mechnikova = Herald of the North-Western State Medical University. 2020; 12(2): 27–38 (In Russ.)]. https://dx.doi.org/10.17816/mechnikov202012227-38. EDN: LQZNNL.
12. Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. с соавт. Международный регистр «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-COV-2» (AКТИВ) и регистр «Анализ госпитализаций коморбидных пациентов инфицированных в период второй волны SARS-COV-2» (AКТИВ 2). Российский кардиологический журнал. 2021; 26(3): 102–113. [Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G. et al. International register «Dynamics analysis of comorbidities in SARS-CoV-2 survivors» (AKTIV SARS-CoV-2): analysis of 1000 patients. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(3): 102–113 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2021-4358. EDN: ATQSNN.
13. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Минздрав России. Доступ: https://minzdrav.gov.ru/ministry/med_covid19 (дата обращения – 01.09.2022). [Interim guidelines «Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)». Ministry of Healthcare of Russia.URL: https://minzdrav.gov.ru/ministry/med_covid19 (date of access – 01.09.2022) (In Russ.)].
About the Autors
Irina M. Sukhomlinova, therapist, pulmonologist at Hospital for War Veterans, competitor of the Department of propaedeutics of internal diseases, gastroenterology and dietology named after S.M. Ryss, I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia. Address: 193079, Saint Petersburg, 21/2 Narodnaya Str. E-mail: sukhomlinova2021@list.ru. ORCID: https://orcid.org/0000-0003-2325-8971
Igor G. Bakulin, Dr. med. habil., professor, head of the Department of propaedeutics of internal diseases, gastroenterology and dietology named after S.M. Ryss, I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia. Address: 195067, Saint Petersburg, 47 Piskarevsy Avenue. E-mail: igbakulin@yandex.ru.
ORCID: https://orcid.org/0000-0002-6151-202. SPIN-code: 5283-2032. Scopus Author ID: 6603812937. ResearcherID: Р-4453-2014
Maxim Yu. Kabanov, Dr. med. habil., professor of the Department of general surgery, I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, head of Hospital for War Veterans. Address: 193079, Saint Petersburg, 21/2 Narodnaya Str. ORCID: https://orcid.org/0000-0001-9763-8497
Similar Articles
